Werewolf Therapeutics, Inc. (HOWL)
NASDAQ$1.2
Market Cap
$53.48M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
619 of 924
Rank in Industry
356 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
HOWL Insider Trading Activity
HOWL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a …
Insider Activity of Werewolf Therapeutics, Inc.
Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $0 worth of Werewolf Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $50.56M and sold $40,242 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,853,000 shares for transaction amount of $4.1M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2023‑01‑06.
List of Insider Buy and Sell Transactions, Werewolf Therapeutics, Inc.
| 2023-01-06 | RA CAPITAL MANAGEMENT, L.P. | director | 1.85M 5.9218% | $2.21 | $4.1M | +17.78% | ||
| 2021-12-15 | Sale | Leonard Reid | Chief Operating Officer | 3,000 0.0157% | $13.41 | $40,242 | -65.47% | |
| 2021-06-16 | RA CAPITAL MANAGEMENT, L.P. | 9,285 0.0512% | $13.37 | $124,140 | +0.29% | |||
| 2021-06-15 | RA CAPITAL MANAGEMENT, L.P. | 7,958 0.0452% | $12.95 | $103,056 | +6.61% | |||
| 2021-06-14 | RA CAPITAL MANAGEMENT, L.P. | 306,055 1.727% | $12.75 | $3.9M | +7.62% | |||
| 2021-05-04 | GADICKE ANSBERT | 10 percent owner | 245,000 1.3777% | $16.00 | $3.92M | -12.48% | ||
| 2021-05-04 | EVNIN LUKE | 150,799 0.848% | $16.00 | $2.41M | -12.48% | |||
| 2021-05-04 | RA CAPITAL MANAGEMENT, L.P. | 1.72M 9.6439% | $16.00 | $27.44M | -12.48% | |||
| 2021-05-04 | MPM BioVentures 2014, L.P. | 10 percent owner | 125,759 0.7072% | $16.00 | $2.01M | -12.48% | ||
| 2021-05-04 | Flynn James E | 10 percent owner | 800,000 4.4986% | $16.00 | $12.8M | -12.48% | ||
| 2021-05-04 | Taiho Ventures LLC | 10 percent owner | 312,500 1.7573% | $16.00 | $5M | -12.48% | ||
| 2021-05-04 | Asanuma Sakae | 312,500 1.7573% | $16.00 | $5M | -12.48% | |||
| 2021-05-04 | Lazarus Alon | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | |||
| 2021-05-04 | Arkin Bio Ventures 2 L.P. | 10 percent owner | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | ||
| 2021-05-04 | Longwood Fund III GP, LLC | 10 percent owner | 250,000 1.4058% | $16.00 | $4M | -12.48% | ||
| 2021-05-04 | Sphera Global Healthcare Management LP | 10 percent owner | 475,000 2.671% | $16.00 | $7.6M | -12.48% | ||
| 2020-12-23 | EVNIN LUKE | 15.88M – | $0 | $0 | +1097.36% | |||
| 2020-12-23 | Asanuma Sakae | 7.6M – | $0.46 | $3.5M | +1097.36% | |||
| 2020-12-23 | Lazarus Alon | 7.12M – | $8.00 | $56.97M | +1097.36% |
Total: 19
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Insider Historical Profitability
<0.0001%
| GADICKE ANSBERT | 10 percent owner | 6672183 14.9724% | $8.01M | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | director | 5701056 12.7932% | $6.84M | 5 | 0 | +3.97% |
| EVNIN LUKE | 4284172 9.6137% | $5.14M | 2 | 0 | <0.0001% | |
| MPM BioVentures 2014, L.P. | 10 percent owner | 3187998 7.1539% | $3.83M | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 2552787 5.7285% | $3.06M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$459,011,221 | 33 | 33.04% | $57.94M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
$167,476,357 | 20 | -1.54% | $50.65M | |
$26,736,140 | 20 | -18.64% | $54.85M | |
$20,234,041 | 17 | 2.08% | $56.81M |
HOWL Institutional Investors: Active Positions
| Increased Positions | 40 | +66.67% | 550,969 | +1.71% |
| Decreased Positions | 21 | -35% | 5M | -14.25% |
| New Positions | 11 | New | 146,564 | New |
| Sold Out Positions | 8 | Sold Out | 3M | Sold Out |
| Total Postitions | 79 | +31.67% | 28M | -12.54% |
HOWL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Ra Capital Management, L.P. | $7,620.00 | 13.66% | 6.14M | 0 | 0% | 2024-12-31 |
| Mpm Asset Management Llc | $5,312.00 | 9.52% | 4.28M | 0 | 0% | 2024-12-31 |
| Pfm Health Sciences, Lp | $3,603.00 | 6.46% | 2.91M | -493,282 | -14.51% | 2024-12-31 |
| Mpm Bioimpact Llc | $2,961.00 | 5.31% | 2.39M | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $2,578.00 | 4.62% | 2.08M | -74,842 | -3.48% | 2024-12-31 |
| Blackrock, Inc. | $2,109.00 | 3.78% | 1.7M | +63,382 | +3.87% | 2024-12-31 |
| Vanguard Group Inc | $1,762.00 | 3.16% | 1.42M | +5,439 | +0.38% | 2024-12-31 |
| Rubric Capital Management Lp | $1,654.00 | 2.96% | 1.33M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $871.00 | 1.56% | 702,558 | +16,569 | +2.42% | 2024-12-31 |
| Sphera Funds Management Ltd. | $777.00 | 1.39% | 626,810 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.